Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-981 with Rituximab in Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma
NCT04074330Phase 2Terminated
- Sponsor
- Takeda
- Start
- Oct 2019
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of subasumstat in non-Hodgkin lymphoma (NHL), sponsored by Takeda. Started Oct 2019; status: terminated.
02
Drugs
subasumstat
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04074330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074330.